Skip to main content
Chinese Journal of Hepatology logoLink to Chinese Journal of Hepatology
. 2019 Sep 20;27(9):725–727. [Article in Chinese] doi: 10.3760/cma.j.issn.1007-3418.2019.09.015

非酒精性脂肪性肝病与少肌症关系的研究进展

Research advances in the relationship between nonalcoholic fatty fiver disease and sarcopenia

Yu Rui 1, Shi Qiangwei 2, Wang Chunfeng 1, Chen Lidong 1, Zhang Lianfeng 1,通信作者:
Editor: 孙 宇航
PMCID: PMC12814813  PMID: 31594102

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the common causes for chronic liver diseases, which progress gradually from nonalcoholic type simple fatty liver disease to hepatitis, cirrhosis and even liver failure and hepatocellular carcinoma. Sarcopenia is a progressive disease characterized by reduced skeletal muscle mass and function in association to metabolic dysfunctions. Recent studies have shown that the occurrence and development of NAFLD and sarcopenia are related, and there is a common base for the pathogenesis between the two, which may promote each other for mutual risk factors. This article reviews the current research progress of this field in order to clinically further understand the pathogenesis and intrinsic links between the two to look for appropriate interventions.

Keywords: Non-alcoholic fatty liver disease, Sarcopenia, Insulin resistance, Myokine


非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)是欧美等西方国家最常见的慢性肝脏疾病,发病率在中国也呈上升趋势[1]。NAFLD是一种以弥漫性肝细胞脂肪变为病理特征的临床综合征,与肥胖、胰岛素抵抗、遗传易感性和氧化应激等多种因素密切相关,其疾病谱包括非酒精性单纯性脂肪肝(nonalcoholic simple fatty liver,NAFL)、非酒精性脂肪性肝炎(NASH)及相关肝硬化、肝衰竭和肝细胞癌。相对于NAFL,NASH患者和合并显著肝纤维化的患者更易发展为终末期肝病,是预后不良的重要危险因素[2]。目前,NAFLD的治疗主要以生活方式的干预为主,尽管不少有前景的治疗药物被试用于NASH患者,但均未被证实对50%以上的患者有效,至今尚无一种药物被批准用于治疗NASH[3]。因此,探究NAFLD的预防和治疗方案是当前面临的重要课题。少肌症是一种以骨骼肌量和功能下降为特点并致生活质量下降、残疾及死亡风险增加的一种疾病[4]。少肌症既往被认为是伴随老龄化出现的退行性病变,近年来,人们认识到它是一种伴随代谢功能紊乱的进展性疾病。因少肌症与NAFLD拥有共同的危险因素如肥胖、胰岛素抵抗、静坐生活方式等,越来越多的研究者关注到NAFLD与少肌症的关系,发现少肌症是NAFLD、NASH及肝纤维化发生的重要危险因素[5-9]。同时,也有研究者认为少肌症是肝功能损害的并发症,肝功能损害一方面可改变葡萄糖代谢、脂质氧化、酮类合成和蛋白质分解代谢,导致肌肉组织成分的丢失;另一方面,肝病患者胃肠道功能障碍使得营养摄入不足,造成肌肉无力,限制了体育锻炼,进一步加重了肌肉量的损失,在终末期肝病患者中少肌症发病率可高达60%,合并存在往往提示预后差。NAFLD与少肌症的发病机制存在部分重叠,在疾病发生和发展过程中两者互相作用机制又不甚明确。现对近年来NAFLD与少肌症关系的研究进展进行综述。

一、NAFLD与少肌症的相关性

一项来自韩国的大规模的调查结果显示在少肌症患者中NAFLD的发病率明显高于非少肌症患者,在多因素回归分析中,少肌症与肥胖、胰岛素抵抗同为NAFLD发生的危险因素[9]。基于同一个研究队列,Lee等[7]利用肝纤维化无创预测模型将患者进行了分类,发现少肌症患者中合并肝纤维化的比例明显高于无少肌症患者,少肌症是NAFLD患者发生肝纤维化的独立危险因素。随后,Koo等[6]通过以肝穿刺病理学检查为NAFLD诊断标准的队列进一步验证了少肌症与肝纤维化的关系,并发现少肌症同时亦是NASH发生的独立危险因素。意大利的Petta等[5]也在经肝穿刺病理学确诊的欧洲NAFLD人群中验证了少肌症与肝纤维化的相关性。

二、NAFLD与少肌症可能的发病机制

1.胰岛素抵抗:骨骼肌作为胰岛素介导的葡萄糖摄取的重要器官,在胰岛素抵抗中起了重要作用。少肌症患者肌肉量的减少降低了胰岛素作用的关键细胞靶位,促成了葡萄糖不耐受及促进糖异生作用,加剧了蛋白质分解和进一步肌肉损耗。此外,胰岛素抵抗导致脂肪分解和游离脂肪酸的产生,大量游离脂肪酸可被肝脏和肌肉摄取[10],而胰岛素抵抗所介导的肌肉量减少和因此引起的肌肉摄取游离脂肪酸减少将导致肝脏进一步暴露于和吸收游离脂肪酸,脂肪在肝脏内大量沉积而致NAFLD[11]

2.慢性炎症和氧化应激:国内外学者普遍认为,NAFLD是异位脂肪堆积合并低级别慢性炎症状态的一种病理学表现,慢性炎症可诱导肝细胞氧化应激反应,而NAFLD的发病机制中最经典的学说是“二次打击”学说,其中氧化应激是NAFLD疾病进展过程中对肝脏的一个非常重要的打击,进而发展成为NAFLD、NASH及肝纤维化[12];NAFLD患者肝脏中过多的脂肪酸又可氧化产生氧自由基,引起脂质过氧化并诱导促炎性细胞因子合成,加重体内炎症反应[7]。同时,慢性炎症和氧化应激可通过影响蛋白质合成与分解之间的平衡,诱导细胞凋亡,导致肌肉萎缩[13]。可以认为,慢性炎症和氧化应激是连接NAFLD与少肌症的重要枢纽。

3.肌肉因子:脂肪组织除具有储存脂肪的功能,还是一个重要的内分泌器官,通过分泌多种炎性细胞因子,发挥调控慢性炎症、糖类及脂类代谢等作用,可促进代谢综合征及心血管疾病的发生。与其相对抗的是,占体质量含量近40%的骨骼肌也作为一种内分泌器官,通过其所分泌的多种物质(也称为肌肉因子),建立与其他脏器(如脂肪、肝脏、胰腺、骨骼和脑)的联系。白细胞介素-6是首个被发现的在肌肉收缩时所产生的细胞因子,其水平伴随运动时长以及参与到运动的骨骼肌量以指数方式成比例增加,运动可使血清白细胞介素-6水平升高达100倍,而白细胞介素-6在炎症易感动物模型中被证实了对NAFLD的发生具有保护作用[14]。Irisin是一种由骨骼肌分泌的运动诱导型肌动蛋白,可使机体能量消耗增加而减轻体质量、减少肥胖和胰岛素抵抗[15];此外,Irisin被报道在肥胖患者中与肝脏脂肪变程度呈负相关[16]。过氧化物酶体增殖物激活受体γ辅助激活因子1α主要由骨骼肌生成,在小鼠动物模型中轻度升高过氧化物酶体增殖物激活受体γ辅助激活因子1 α,可对抗老龄化相关的肥胖、糖尿病及可延长寿命[17]。因此,少肌症患者可因肌肉因子分泌量减少而增加患NAFLD的风险。

4.生长激素及胰岛素样生长因子:生长激素(GH)可刺激多数组织产生胰岛素样生长因子-1(IGF-1),协同IGF-1调节脂肪、蛋白质和葡萄糖代谢,在儿童生长发育期及整个生命过程中都发挥要作用。GH/IGF-1是促进人体肌肉合成的重要激素,其分泌受到抑制可导致内脏脂肪沉积和腹型肥胖,肥胖并合并GH分泌低下者则表现出严重的代谢障碍[18]。研究结果显示,GH/IGF-1轴在肝脏也发挥重要作用,GH/IGF-1分泌低下可引起肝脏脂肪沉积、促进NASH及肝纤维化的发展[19]。GH/IGF-1轴可能是少肌症和NAFLD之间的另一关联因素。

5.维生素D缺乏:维生素D缺乏与少肌症关系密切。人体骨骼肌存在维生素D受体,维生素D可通过维生素D受体介导的信号传导调节成肌细胞增殖和分化,在骨骼肌生长和肌肉炎症中发挥重要作用,补充维生素D可增加维生素D受体在骨骼肌中的表达,减少骨骼肌流失。另一方面,越来越多的研究者关注到了维生素与NAFLD的关系。纳入了17项研究的Meta分析结果显示,与对照组相比,NAFLD患者血清维生素D水平较低且维生素D缺乏的发生率更高[20]。随机对照临床研究结果显示,纠正维生素D缺乏可以通过降低血清hs-CRP和甲烷二甲醛水平改善NAFLD患者体内炎症反应[21]。因此,维生素D可作为NAFLD与少肌症关系研究的重要切入点。

6.肠道微生态:肠道和肝脏之间有密切的解剖和功能关系,即所谓的“肠-肝轴”,肠道菌群可以通过“肠-肝轴”参与NAFLD的发生发展。肝脏作为门静脉的首过器官,在肝脏中门静脉供血量占肝脏供血量的70%~75%,肠道细菌代谢产物、内毒素、食物中的抗原等可以通过门静脉运至肝脏被各种免疫细胞所识别。菌群失调导致小肠细菌过度生长,越来越多的细菌代谢产物及其他化合物通过门静脉进入肝脏,触发信号转导级联,释放细胞因子和趋化因子,引起炎症反应、氧化应激和脂质积累,最终导致肝脏脂肪化和纤维化。此外,肠道微生物可以直接调节氨基酸的吸收代谢,并通过释放能够到达骨骼肌组织产生代谢作用的亚油酸,乙酸盐和胆汁盐而对肌肉蛋白质的合成产生间接作用。通过对营养不良儿童的肠道微生物群的特征研究结果显示,营养不良患者中微生物多样性减低和致病菌过量表达,通过饮食干预往往难以改善。这表明,肠道微生物群的组成及其功能可能直接参与改变营养状况,与肌肉萎缩和少肌症密切相关。

7.缺乏运动:少肌症患者运动能力下降,往往伴随久坐生活方式,易合并肥胖及代谢综合征。此外,同前所述,骨骼肌通过分泌“肌肉因子”而作为内分泌器官发挥其功能,通过运动可以促进肌肉纤维的生长及此类因子的释放,缺乏运动的患者往往因为肌肉量减少及细胞因子分泌量减少而处于慢性炎症状态。Meta分析结果显示规律运动,即使在体质量无明显减轻的情况下,仍可有效降低肝脏脂肪含量,运动是NAFLD有效且低成本的治疗方案。

三、结语

随着人口老龄化及生活方式的改变,NAFLD及少肌症发病率逐渐升高。少肌症不仅仅是肝功能损害导致的代谢改变的结果,也是NAFLD发展至NASH及纤维化的的独立预测因素。两者在发病过程中具有某些共同的机制,互为因果,关系错综复杂。其具体机制目前仍未完全阐明,深入的研究将有助于阐释NAFLD与少肌症的病因和发病过程。同时针对此研究干预措施以期可以预防或减少终末期肝病,提高患者生存质量。

作者贡献声明

于蕊、师强伟:综述;王春峰、陈立冬、张连峰:审校

利益冲突

所有作者均声明不存在利益冲突

参考文献

  • [1].Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014,60(6):2099-2108. DOI: 10.1002/hep.27406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease[J]. Gastroenterology, 2015,149(2):389-397. DOI: 10.1053/j.gastro.2015.04.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Rinella ME. Nonalcoholic fatty liver disease: a systematic review[J]. JAMA, 2015,313(22):2263-2273. DOI: 10.1001/jama.2015.5370. [DOI] [PubMed] [Google Scholar]
  • [4].Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010,39(4):412-423. DOI: 10.1093/ageing/afq034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017,45(4):510-518. DOI: 10.1111/apt.13889. [DOI] [PubMed] [Google Scholar]
  • [6].Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J]. J Hepatol, 2017,66(1):123-131. DOI: 10.1016/j.jhep.2016.08.019. [DOI] [PubMed] [Google Scholar]
  • [7].Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011)[J]. Hepatology, 2016,63(3):776-786. DOI: 10.1002/hep.28376. [DOI] [PubMed] [Google Scholar]
  • [8].Hashimoto Y, Osaka T, Fukuda T, et al. The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes[J]. Endocrine Journal, 2016,63(10):877-884. DOI: 10.1507/endocrj.EJ16-0124. [DOI] [PubMed] [Google Scholar]
  • [9].Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011)[J]. Journal of Hepatology, 2015,63(2):486-493. DOI: 10.1016/j.jhep.2015.02.051. [DOI] [PubMed] [Google Scholar]
  • [10].Jocken JW, Langin D, Smit E, et al. Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state[J]. J Clin Endocrinol Metab, 2007,92(6):2292-2299. DOI: 10.1210/jc.2006-1318. [DOI] [PubMed] [Google Scholar]
  • [11].Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes[J]. Diabetes, 2002,51(3):797-802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology, 2010,52(5):1836-1846. DOI: 10.1002/hep.24001. [DOI] [PubMed] [Google Scholar]
  • [13].Phillips T, Leeuwenburgh C. Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction[J]. FASEB J, 2005,19(6):668-670. DOI: 10.1096/fj.04-2870fje. [DOI] [PubMed] [Google Scholar]
  • [14].Miller AM, Wang H, Bertola A, et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice[J]. Hepatology, 2011,54(3):846-856. DOI: 10.1002/hep.24517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J]. Nature, 2012,481(7382):463-468. DOI: 10.1038/nature10777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults[J]. J Hepatol, 2013,59(3):557-562. DOI: 10.1016/j.jhep.2013.04.030. [DOI] [PubMed] [Google Scholar]
  • [17].Wenz T, Rossi SG, Rotundo RL, et al. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging[J]. Proc Natl Acad Sci U S A, 2009,106(48):20405-20410. DOI: 10.1073/pnas.0911570106. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • [18].Berryman DE, Glad CA, List EO, et al. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations[J]. Nat Rev Endocrinol, 2013,9(6):346-356. DOI: 10.1038/nrendo.2013.64. [DOI] [PubMed] [Google Scholar]
  • [19].Koehler E, Swain J, Sanderson S, et al. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients[J]. Liver Int, 2012,32(2):279-286. DOI: 10.1111/j.1478-3231.2011.02637.x. [DOI] [PubMed] [Google Scholar]
  • [20].Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2013,38(3):246-254. DOI: 10.1111/apt.12377. [DOI] [PubMed] [Google Scholar]
  • [21].Sharifi N, Amani R, Hajiani E, et al. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial[J]. Endocrine, 2014,47(1):70-80. DOI: 10.1007/s12020-014-0336-5. [DOI] [PubMed] [Google Scholar]

Articles from Chinese Journal of Hepatology are provided here courtesy of Second Affiliated Hospital of Chongqing Medical University

RESOURCES